A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
Phase
3Span
386 weeksSponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNova Lima, Minas Gerais
Recruiting
1-1 of 1